ERBB2 and breast carcinoma: To achieve this, we used the G1 arresting CDK4/6 inhibitor palbociclib, which is used in the treatment of hormone (oestrogen and/or progesterone) receptor‐positive HER2‐negative breast cancer (Ro et al, 2015).